Bucindolol
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number | 71119-11-4 |
PubChem (CID) | 51045 |
ChemSpider | 46266 |
UNII | E9UO06K7CE |
ChEMBL | CHEMBL2107546 |
ECHA InfoCard | 100.114.291 |
Chemical and physical data | |
Formula | C22H25N3O2 |
Molar mass | 363.45 g/mol |
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[1][3]
See also
References
- 1 2 "formularyjournal.modernmedicine.com".
- ↑ Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185.
- ↑ "FDA rejects bucindolol and questions trial integrity « CardioBrief".
This article is issued from Wikipedia - version of the 6/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.